JP6389893B2 - 神経系に対する損傷に関与する疾病を治療するためのオメガ3脂肪酸の組成物 - Google Patents
神経系に対する損傷に関与する疾病を治療するためのオメガ3脂肪酸の組成物 Download PDFInfo
- Publication number
- JP6389893B2 JP6389893B2 JP2016540609A JP2016540609A JP6389893B2 JP 6389893 B2 JP6389893 B2 JP 6389893B2 JP 2016540609 A JP2016540609 A JP 2016540609A JP 2016540609 A JP2016540609 A JP 2016540609A JP 6389893 B2 JP6389893 B2 JP 6389893B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- glaucoma
- epa
- omega
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 98
- 201000010099 disease Diseases 0.000 title description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 43
- 235000020660 omega-3 fatty acid Nutrition 0.000 title description 41
- 229940012843 omega-3 fatty acid Drugs 0.000 title description 41
- 239000006014 omega-3 oil Substances 0.000 title description 22
- 230000006378 damage Effects 0.000 title description 20
- 210000000653 nervous system Anatomy 0.000 title description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 95
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 67
- 208000010412 Glaucoma Diseases 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 51
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 46
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 46
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 45
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 45
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 44
- 210000001328 optic nerve Anatomy 0.000 claims description 37
- 208000028389 Nerve injury Diseases 0.000 claims description 31
- 230000008764 nerve damage Effects 0.000 claims description 31
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 24
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 24
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000003435 Optic Neuritis Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 229940114079 arachidonic acid Drugs 0.000 claims description 5
- 235000021342 arachidonic acid Nutrition 0.000 claims description 5
- 239000000306 component Substances 0.000 claims 5
- 235000012041 food component Nutrition 0.000 claims 1
- 239000005417 food ingredient Substances 0.000 claims 1
- 239000005426 pharmaceutical component Substances 0.000 claims 1
- 230000000007 visual effect Effects 0.000 description 49
- 230000004438 eyesight Effects 0.000 description 36
- 208000033808 peripheral neuropathy Diseases 0.000 description 33
- 201000001119 neuropathy Diseases 0.000 description 29
- 230000007823 neuropathy Effects 0.000 description 29
- 230000004054 inflammatory process Effects 0.000 description 28
- 206010061218 Inflammation Diseases 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 24
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 20
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 20
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 20
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 19
- 210000001508 eye Anatomy 0.000 description 19
- 210000005036 nerve Anatomy 0.000 description 18
- 230000004304 visual acuity Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 230000004410 intraocular pressure Effects 0.000 description 14
- 150000003431 steroids Chemical class 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- -1 sachets Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 230000006872 improvement Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 230000008733 trauma Effects 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000007502 anemia Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 9
- 206010039705 Scleritis Diseases 0.000 description 9
- 230000008397 ocular pathology Effects 0.000 description 9
- 208000030768 Optic nerve injury Diseases 0.000 description 8
- 206010046851 Uveitis Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004424 eye movement Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000006186 oral dosage form Substances 0.000 description 8
- 206010029240 Neuritis Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000019736 Cranial nerve disease Diseases 0.000 description 6
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001384 anti-glaucoma Effects 0.000 description 6
- 210000001428 peripheral nervous system Anatomy 0.000 description 6
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 210000003994 retinal ganglion cell Anatomy 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 208000019743 Cranial nerve injury Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 206010039203 Road traffic accident Diseases 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006806 disease prevention Effects 0.000 description 4
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047555 Visual field defect Diseases 0.000 description 2
- 206010047627 Vitamin deficiencies Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000014337 facial nerve disease Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- JIWBIWFOSCKQMA-GFRMADBLSA-N (6e,9e,12e,15e)-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\CCCCC(O)=O JIWBIWFOSCKQMA-GFRMADBLSA-N 0.000 description 1
- KBGYPXOSNDMZRV-NKIRVBODSA-N (7z)-hexadeca-7,10,13-trienoic acid Chemical compound CCC=CCC=CC\C=C/CCCCCC(O)=O KBGYPXOSNDMZRV-NKIRVBODSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- HQPCSDADVLFHHO-UHFFFAOYSA-N Cis-8,11,14,17-Eicosatetraenoic acid Chemical compound CCC=CCC=CCC=CCC=CCCCCCCC(O)=O HQPCSDADVLFHHO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000022994 Isolated optic neuritis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019545 cooked cereal Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- PQZTVWVYCLIIJY-UHFFFAOYSA-N diethyl(propyl)amine Chemical group CCCN(CC)CC PQZTVWVYCLIIJY-UHFFFAOYSA-N 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004399 eye closure Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- SBHCLVQMTBWHCD-UHFFFAOYSA-N icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(O)=O SBHCLVQMTBWHCD-UHFFFAOYSA-N 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000017802 other dietary supplement Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 208000016997 secondary vasculitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/08—Food product presented as a kit of parts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/187—Eicosapentaenoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Description
顔面神経障害は、顔の表情及び閉眼の筋肉の弱さを生み出す。自発的な閉眼は可能でないかも知れず、結果として角膜及び結膜に対する損傷を生じ得る。
強膜炎、甲状腺眼疾患、慢性ブドウ膜炎及び結膜炎のような疾患は、炎症に起因する。現在の治療は、ステロイド及び免疫抑制剤を含む。
視神経損傷は、主に緑内障、局所貧血(ischaemia)、炎症又は外傷に起因して発生し得る。現在、これらの患者において軸索損傷を限定して神経機能を改善する治療は存在しない。
緑内障は世界中において失明の第2位の原因であり、約8700万人の人々を失明させている。これは米国の人口の1〜2%に影響を与える。
1)高圧緑内障(原発開放隅角緑内障)と常圧緑内障(正常眼圧緑内障)に細分化される開放隅角緑内障
2)閉塞隅角緑内障
3)続発性緑内障
IONの95%は、非炎症性の小血管疾患に対して二次的である。残りは二次的な血管炎に起因する。非動脈炎性前部虚血性視神経症(NAION)は、50歳の年齢を超える患者における急性視神経症の最も一般的な原因である。これは、10万人当たり10人の人々にまで影響を及ぼす。症状は、視覚の急性の片側性の無痛を含む。視野内の任意の領域が影響を受け得る。 IONを有する患者の50%より多くが、狭窄視野を有する盲目(<20/200視覚)である。
視神経炎は、若年成人に最も頻繁に発生し、多発性硬化症に関連付けられ得る視神経の急性炎症性脱髄疾患である。良好な機能的視力回復が殆どの患者に見られるにもかかわらず、一部の患者は回復することができない(5?10%)。視神経炎は、患者の20%までにおいて、多発性硬化症の初期の提示である。眼科医は通常、多発性硬化症関連の視覚症状を有する患者を診察する最初の医師である。これは血液脳関門を横断する免疫細胞の血管周囲浸潤を伴う自己免疫疾患である。これらの免疫細胞は、ミエリンを破壊して脱髄を引き起こす。炎症性細胞及び体液性免疫機構は、視神経炎において主要な役割を果たす。
強膜炎、甲状腺眼疾患、慢性ブドウ膜炎及び結膜炎のような疾患は、炎症に起因する。現在の治療は、ステロイド及び免疫抑制剤を含む。
本発明は、神経損傷を有する患者における視力及び視野を改善するための問題に直面し、特に緑内障の炎症/局所貧血又は外傷に起因する視神経損傷に直面する。
従って、本発明の第一の態様によれば、以下本発明の組成物とする、少なくとも3gのオメガ3脂肪酸、より好適には5gのオメガ3脂肪酸を含む組成物が提供される。
エイコサテトラエン酸(ETA) 20:4(n−3)
全シス‐8,11,14,17‐エイコサテトラエン酸 304
エイコサトリエン酸(ETE) 20:3(n−3)
全シス‐11,14,17‐エイコサトリエン酸 306
ステアリドン酸(SDA) 18:4(n−3)
全シス‐6,9,12,15‐オクタデカテトラエン酸 276
リノレン酸(ALA) 18:3(n−3)
全シス‐9,12,15‐オクタデカトリエン酸 278
ヘキサデカトリエン酸(HTA) 16:3(n−3)
全シス‐7,10,13‐ヘキサデカトリエン酸 250
本発明の第三の態様は、治療における使用又は薬物若しくは薬剤としての使用のための、本発明の組成物又は部分のキットを指す。
本明細書において使用されるように、「活性成分」、「活性物質」、「活性医薬物質」、「活性原理(principle)」又は「活性医薬成分」は、疾病の診断、治癒、緩和、治療若しくは予防において潜在的に診断薬理学的活性若しくは別の異なる効果を提供する任意の成分、又は人体及び他の動物の構造及び機能に影響を与える任意の成分を意味する。前記用語は、薬剤の同化(elaboration)における化学変化を促進し、特異的活性または効果をもたらす予測される変形された形態において薬剤に存在する、これらの成分を含む。
(実施例)
Claims (11)
- 視神経損傷の治療、改善又は予防における使用のための、1:1から5:1までのEPA:DHAの質量比における、少なくとも5gのエイコサペンタエン酸及びドコサヘキサエン酸を含む組成物又は成分のセット。
- 視神経損傷が緑内障に起因する視神経損傷、虚血性視神経症(ION)及び視神経炎、又はこれらの任意の組み合わせから構成される群から選択される、請求項1に記載の組成物又は成分のセット。
- 視神経炎の治療、改善又は予防における使用のための、請求項1又は2に記載の組成物又は成分のセット。
- 緑内障の治療、改善又は予防における使用のための、請求項1に記載の組成物又は成分のセット。
- 投与されるエイコサペンタエン酸及びドコサヘキサエン酸の量が一日当たり5〜15gの間を含む(comprised between)、請求項1乃至4のいずれかに記載の組成物又は成分のセット。
- 投与されるエイコサペンタエン酸及びドコサヘキサエン酸の量が一日当たり7.5gより上である、請求項1乃至5のいずれかに記載の組成物又は成分のセット。
- 投与されるエイコサペンタエン酸及びドコサヘキサエン酸の量が一日当たり7.5〜10gの間を含む、請求項1乃至6のいずれかに記載の組成物又は成分のセット。
- 投与されるエイコサペンタエン酸の量が一日当たり3.0gより上である、請求項1乃至7のいずれかに記載の組成物又は成分のセット。
- 前記組成物が医薬組成物であり、又は前記成分のセットが医薬成分のセットである、請求項1乃至8のいずれかに記載の組成物又は成分のセット。
- 前記組成物が食品組成物であり、又は前記成分のセットが食品成分のセットである、請求項1乃至9のいずれかに記載の組成物又は成分のセット。
- エイコサペンタエン酸及びドコサヘキサエン酸の量は、血液中のアラキドン酸/エイコサペンタエン酸の質量比が0.8〜3の範囲内、好適には1〜1.5の範囲内にあるようなものである、請求項1乃至10のいずれかに記載の組成物又は成分のセット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/077356 WO2015090394A1 (en) | 2013-12-19 | 2013-12-19 | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017501169A JP2017501169A (ja) | 2017-01-12 |
JP6389893B2 true JP6389893B2 (ja) | 2018-09-12 |
Family
ID=50137601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016540609A Active JP6389893B2 (ja) | 2013-12-19 | 2013-12-19 | 神経系に対する損傷に関与する疾病を治療するためのオメガ3脂肪酸の組成物 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20160331712A1 (ja) |
EP (1) | EP3082795B1 (ja) |
JP (1) | JP6389893B2 (ja) |
KR (1) | KR101898358B1 (ja) |
CN (1) | CN105828813A (ja) |
AU (1) | AU2013407946B2 (ja) |
BR (1) | BR112016014182A2 (ja) |
CA (1) | CA2934600C (ja) |
CY (1) | CY1123942T1 (ja) |
DK (1) | DK3082795T3 (ja) |
ES (1) | ES2813383T3 (ja) |
HR (1) | HRP20201221T1 (ja) |
HU (1) | HUE050205T2 (ja) |
IL (1) | IL246254B (ja) |
LT (1) | LT3082795T (ja) |
MX (1) | MX2016007803A (ja) |
MY (1) | MY185412A (ja) |
PH (1) | PH12016501159A1 (ja) |
PL (1) | PL3082795T3 (ja) |
PT (1) | PT3082795T (ja) |
RS (1) | RS60862B1 (ja) |
RU (1) | RU2667640C1 (ja) |
UA (1) | UA117274C2 (ja) |
WO (1) | WO2015090394A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
CN114786480B (zh) * | 2019-10-30 | 2024-03-29 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
AU2021217358A1 (en) | 2020-02-06 | 2022-09-08 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
EP4329753A1 (en) | 2021-04-30 | 2024-03-06 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
US20100254951A1 (en) * | 2005-02-22 | 2010-10-07 | Mochida Pharmaceutical Co., Ltd. | Nerve Regeneration Promoting Agent |
JP5240757B2 (ja) * | 2005-02-22 | 2013-07-17 | 持田製薬株式会社 | 神経再生促進剤 |
US20070265340A1 (en) * | 2006-01-05 | 2007-11-15 | Shalwitz Robert A | Treatment of fatty liver |
EP1900378A1 (en) | 2006-08-31 | 2008-03-19 | Novartis AG | Pharmaceutical compositions for the treatment of fungal infections |
JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
BRPI0924012A2 (pt) * | 2009-04-17 | 2019-09-24 | Cela Vista Pharmaceuticals Ltd | processo para obtenção de uma composição rica em ácidos graxos ômega 3 de um óleo de origem marinha, com um teor de af interior 90 mg/g composição, suplemento nutricional produto alimentar, composição farmacêutica, e, uso de um composto |
US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
RU2597793C2 (ru) * | 2011-01-25 | 2016-09-20 | Нестек С.А. | Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных |
BR112013020802A2 (pt) * | 2011-02-18 | 2016-10-04 | Nestec Sa | métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
BR112014005546A2 (pt) * | 2011-09-12 | 2017-03-21 | Georgiou Tassos | ácidos graxos ômega para tratamento de doenças |
-
2013
- 2013-12-19 AU AU2013407946A patent/AU2013407946B2/en active Active
- 2013-12-19 BR BR112016014182A patent/BR112016014182A2/pt not_active Application Discontinuation
- 2013-12-19 UA UAA201607999A patent/UA117274C2/uk unknown
- 2013-12-19 RS RS20200971A patent/RS60862B1/sr unknown
- 2013-12-19 PT PT138301841T patent/PT3082795T/pt unknown
- 2013-12-19 MY MYPI2016702245A patent/MY185412A/en unknown
- 2013-12-19 DK DK13830184.1T patent/DK3082795T3/da active
- 2013-12-19 KR KR1020167019609A patent/KR101898358B1/ko active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077356 patent/WO2015090394A1/en active Application Filing
- 2013-12-19 PL PL13830184T patent/PL3082795T3/pl unknown
- 2013-12-19 MX MX2016007803A patent/MX2016007803A/es unknown
- 2013-12-19 CN CN201380081739.3A patent/CN105828813A/zh active Pending
- 2013-12-19 HU HUE13830184A patent/HUE050205T2/hu unknown
- 2013-12-19 US US15/106,475 patent/US20160331712A1/en not_active Abandoned
- 2013-12-19 LT LTEP13830184.1T patent/LT3082795T/lt unknown
- 2013-12-19 CA CA2934600A patent/CA2934600C/en active Active
- 2013-12-19 RU RU2016129079A patent/RU2667640C1/ru active
- 2013-12-19 EP EP13830184.1A patent/EP3082795B1/en active Active
- 2013-12-19 ES ES13830184T patent/ES2813383T3/es active Active
- 2013-12-19 JP JP2016540609A patent/JP6389893B2/ja active Active
-
2016
- 2016-06-15 PH PH12016501159A patent/PH12016501159A1/en unknown
- 2016-06-15 IL IL246254A patent/IL246254B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,354 patent/US10905671B2/en active Active
-
2020
- 2020-08-04 HR HRP20201221TT patent/HRP20201221T1/hr unknown
- 2020-08-13 CY CY20201100758T patent/CY1123942T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013407946A2 (en) | 2016-08-25 |
IL246254A0 (en) | 2016-07-31 |
UA117274C2 (uk) | 2018-07-10 |
IL246254B (en) | 2021-04-29 |
RU2016129079A (ru) | 2018-01-24 |
EP3082795B1 (en) | 2020-05-20 |
JP2017501169A (ja) | 2017-01-12 |
WO2015090394A1 (en) | 2015-06-25 |
PT3082795T (pt) | 2020-08-27 |
ES2813383T3 (es) | 2021-03-23 |
CY1123942T1 (el) | 2022-03-24 |
HUE050205T2 (hu) | 2020-11-30 |
PL3082795T3 (pl) | 2020-11-16 |
CN105828813A (zh) | 2016-08-03 |
LT3082795T (lt) | 2020-11-10 |
BR112016014182A2 (pt) | 2017-08-08 |
PH12016501159A1 (en) | 2016-08-15 |
AU2013407946B2 (en) | 2017-09-07 |
RU2667640C1 (ru) | 2018-09-21 |
US20160331712A1 (en) | 2016-11-17 |
EP3082795A1 (en) | 2016-10-26 |
HRP20201221T1 (hr) | 2020-11-13 |
MX2016007803A (es) | 2017-08-10 |
CA2934600C (en) | 2018-11-20 |
DK3082795T3 (da) | 2020-08-24 |
KR101898358B1 (ko) | 2018-09-12 |
US10905671B2 (en) | 2021-02-02 |
KR20160093729A (ko) | 2016-08-08 |
CA2934600A1 (en) | 2015-06-25 |
AU2013407946A1 (en) | 2016-08-04 |
RS60862B1 (sr) | 2020-11-30 |
US20190192466A1 (en) | 2019-06-27 |
MY185412A (en) | 2021-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10905671B2 (en) | Method of using omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
JP7006990B2 (ja) | 眼障害の処置のための組成物及び方法 | |
EP2755647B1 (en) | Use of omega fatty acids for treating disease | |
ES2585066T3 (es) | Composiciones para el tratamiento de trastornos neurológicos | |
US20160067204A1 (en) | Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders | |
JP2023184569A (ja) | ドライアイ疾患及び瞼板腺炎の治療のための組成物 | |
KR20230004545A (ko) | Lpc-dha 및 lpc-epa가 풍부한 크릴 오일 조성물 | |
US20030187058A1 (en) | Combination of lipoic acids and conjugated acids for treating diabetic disorders | |
JP7038437B2 (ja) | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 | |
JP2020138964A (ja) | 近視進行抑制剤、機能性食品及び眼科用組成物 | |
KR20180118951A (ko) | 안구 질환 예방 또는 개선용 건강기능식품 조성물 | |
KR20240036651A (ko) | 산화성 망막 질환의 진행을 억제하는 방법 | |
KR20220152237A (ko) | 장쇄 지방산을 포함하는 안구 건강용 조성물 및 방법 | |
WO2015165507A1 (en) | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio | |
JP2021536439A (ja) | 眼障害及び皮膚疾患の処置のための眼科用組成物及び方法 | |
WO2005046668A1 (ja) | 言語障害予防・治療剤 | |
TWI708602B (zh) | 組合物用於製備改善顏色辨識能力或改善色差辨識能力之藥物之用途 | |
Hsu et al. | Effects of Supplementation with Lutein Plus Docosahexaenoic Acid Oral Complex on Eye Dryness, Visual Function, and Memory Function in Healthy Subjects: A Single‐Arm Clinical Trial | |
PL239957B1 (pl) | Emulsja typu olej w wodzie do zastosowania w kroplach do oczu jako nośnik dla okulistycznych substancji leczniczych rozpuszczalnych w olejach | |
CN117320714A (zh) | 用于治疗眼部疾病的方法和组合物 | |
JP2020145941A (ja) | アレルギー性鼻炎抑制用組成物 | |
WO2012060860A1 (en) | Treatment of ocular and cerebral ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161014 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180719 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180808 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180820 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6389893 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |